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Abstract 
2-methylene-1,3-dioxepane (MDO) and different vinyl ether (VE) monomers were 
successfully copolymerized by free-radical radical ring-opening copolymerization (rROP) to 
yield P(MDO-co-VE) copolymers with Mn = 7 000–13 000 g.mol
-1
 and high molar fractions 
of MDO (FMDO = 0.7–0.9). By using VE derivatives of different aqueous solubilities or by 
grafting PEG chains onto the copolymers by “click” chemistry via azide-containing VE units, 
hydrophobic, amphiphilic or even water-soluble copolymers were obtained. The different 
copolymers were then formulated into nanoparticles by nanoprecipitation using Pluronics for 
hydrophobic copolymers, without surfactant for amphiphilic copolymers, or blended with 
PMDO for water-soluble copolymers. Most of the copolymers led to nanoparticles with 
average diameters in the 130–250 nm with narrow particle size distributions and satisfying 
colloidal stability for a period of at least 1-2 weeks and up to 6 months. The copolymers were 
successfully degraded under accelerated, hydrolytic or enzymatic conditions. Hydrophobic 
copolymers led to degradation kinetics in PBS similar to that of PCL and complete 
degradation (-95% in Mn decrease) was observed in the presence of enzymes (lipases). 
Preliminary cytotoxicity assays were performed on endothelial cells (HUVEC) and 
macrophages (J774.A1) and revealed high cell viabilities at 0.1 mg.mL
-1
. 
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Introduction 
Developing materials for biomedical applications is the subject of extensive research. In 
particular, (bio)degradable polymers have aroused keen attention because not only they can be 
used in (nano)medicine but also in a wide range of other applications such as microelectronics 
and environmental protection.
1-3
 For drug delivery and tissue engineering, polymers should 
follow some criteria. They should be: (i) biocompatible, to ensure compatibility with the 
biological medium; (ii) well-defined, for batch-to-batch reproducibility purposes; (iii) 
biodegradable, at least for some applications where their accumulation/resistance may be 
detrimental and (iv) possibly functionalizable with molecules of interest to confer advanced 
properties. 
 The most studied biodegradable polymers are certainly aliphatic polyesters, which are 
synthesized by ring-opening polymerization (ROP) of cyclic monomers (e.g., lactide, 
glycolide, caprolactone, etc.). Notably, these (co)polymers are approved by the Food and 
Drug Administration (FDA) for use in humans.
4
 Although they present important advantages 
and they are still considered as the gold standards, their synthesis is not always 
straightforward and their functionalization is relatively limited and/or rather tedious.
5-8
 On the 
other hand, vinyl polymers present numerous advantages such as their facile synthesis, the 
wide range of compositions and architectures that can be easily obtained, especially by 
reversible deactivation radical polymerization (RDRP), and their easiness of functionalization. 
However, their carbon-carbon backbone resists degradation which may be detrimental if 
biomedical applications are envisioned. Thus, combining the best of two worlds by 
developing synthetic strategies to generate (bio)degradable vinyl materials would be 
advantageous and would be a real step forward towards the use of vinyl materials in 
biomedical applications. Among the different strategies to confer degradability to vinyl 
polymers,
9
 radical ring-opening polymerization (rROP) is perhaps the most potent one.
10
 It 
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relies on the polymerization of cyclic monomers, mainly cyclic ketene acetals (CKAs)
10,11
 and 
sulfide cyclic methacrylates,
12
 that lead to insertion of labile groups (e.g., ester, disulfide, 
thioester) in the polymer backbone through a radical ring-opening mechanism. CKAs are 
probably the most studied monomers for rROP. They were the subject of extensive research in 
the 1980s
13-17
 and recently regained interest to obtain degradable vinyl copolymers for 
different bio-related applications.
18-29
 Such monomers can indeed be copolymerized, by free-
radical polymerization or RDRP, with certain traditional vinyl monomers (e.g., vinyl acetate, 
methacrylic esters) to yield degradable or segmentable copolymers; depending on the amount 
of labile groups inserted. One of the main limitations of rROP from CKAs, however, is their 
unfavorable reactivity ratios when copolymerized with vinyl monomers.
10
 Thus, a large 
excess of CKA is required in the initial comonomer feed to ensure a sufficient amount in the 
resulting copolymer. Yet, the final molar fraction of CKA is often limited and gradient-type 
copolymers are usually obtained. 
In this context, we recently reported on a quasi-ideal radical ring-opening 
copolymerization system between CKA and vinyl ether (VE) derivatives.
30
 We showed that 
free-radical copolymerization of 2-methylene-1,3-dioxepane (MDO) and butyl vinyl ether 
(BVE) gave much more favourable reactivity ratios (rMDO = 0.73 and rBVE = 1.61) and 
resulted in nearly random copolymers with tuneable MDO contents, up to high values (~90 
mol.%). Importantly, given many functional VE derivatives are commercially available, this 
approach was readily applied to the synthesis of: (i) fluorescent and amphiphilic copolymers 
obtained by post-functionalization strategies (e.g., nucleophilic substitution, “click” 
chemistry); (ii) bioelastomers with suitable properties for tissue engineering applications by 
using a difunctional VE and (iii) antibacterial films.  
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Figure 1. Synthesis of degradable vinyl copolymers by nearly ideal free-radical ring-opening 
copolymerization between 2-methylene-1,3-dioxepane (MDO) and vinyl ether (VE) 
derivatives. 
 
Herein, given the very few examples of degradable vinyl materials for biomedical purposes 
described in the literature, we explored the potential of this new copolymerization system 
between MDO and VE derivatives (Figure 1) for the preparation degradable copolymer 
nanoparticles for potential drug delivery applications. A series of hydrophobic, amphiphilic or 
water-soluble P(MDO-co-VE) copolymers obtained by different synthetic routes were 
prepared by rROP and formulated into nanoparticles whose colloidal properties and 
preliminary cytotoxicity were investigated. Degradation of the different copolymers were also 
monitored under different conditions to assess the degradability of those materials. Not only 
this study reports the preparation of a new class of degradable polymer nanoparticles with 
interesting potential in the biomedical field, but it also represents the first example of 
hydrolytically and enzymatically degradable, functional vinyl copolymers mainly composed 
of CKA units (PCL-like).  
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Experimental part 
1. Materials 
All reagents and solvents were used as received except CuBr which was purified by stirring in 
acetic acid, washed with ethanol then diethyl ether. Bromoacetaldehyde dimethyl acetal 
(97 %), 1,4-butanediol (99 %), para-toluenesulfonic acid monohydrate (≥ 98.5 %), Aliquat® 
336, potassium tert-butoxide (> 98 %), 2-chloroethyl vinyl ether (CEVE) (99 %), 
tetra(ethylene glycol) methyl vinyl ether (TEGVE), NaN3 (99 %), 4-pentynoic acid (95 %), 4-
(dimethylamino)pyridine (DMAP) (≥ 99 %), N,N’-dicyclohexylcarbodiimide (DCC) (99 %), 
N,N,N’,N’’,N’’-pentamethyldiethylenetriamine (PMDETA) (99 %), CuBr (98 %), 1,1’-
carbonyldiimidazole (CDI) (reagent grade), poly(ethylene glycol) methyl ether (MePEG) 
(Mn = 2 000 g.mol
-1
 and Mn = 750 g.mol
-1
), lipases immobilized from Candida antarctica 
(> 2 U.mg
-1
), phosphate buffer saline (PBS) 1X, pH = 7.4 and anhydrous solvents were 
purchased from Sigma Aldrich (Merck). 2-methylene-1,3-dioxepane (MDO) monomer was 
prepared by adapting a previously published method, using the cyclic bromoacetal as 
intermediate.
31
 Alkyne-MePEG750 was prepared according to a previous report.
30
 
Diethylazobisisobutyrate (DEAB) was kindly supplied by Arkema. Aminopropylvinylether 
was kindly supplied by BASF. Deuterated chloroform was obtained from Eurisotop. All other 
solvents were purchased from Carlo-Erba at the highest grade. 
2. Analytical Methods 
Nuclear Magnetic Resonance Spectroscopy (NMR). NMR spectroscopy was performed in 
5 mm diameter tubes in CDCl3 at 25 °C. 
1
H spectroscopy was performed on a Bruker Avance 
spectrometer at 300 MHz. The chemical shifts are reported in ppm (δ units), and internal 
solvent signal (δ = 7.26 ppm) was used as reference. The abbreviations used to designate the 
multiplicities are: s = singlet, d = doublet, t = triplet, m = multiplet. 
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Size Exclusion Chromatography (SEC). SEC of copolymers was performed on a Tosoh 
EcoSEC HLC-8320 GPC with two columns from Agilent (PL-gel MIXED-D 300  7.5 mm, 
beads diameter 5 m; linear part 400 to 4  105 g.mol-1). Analyses were performed at 35 °C in 
chloroform (HPLC grade) at a flow-rate of 1 mL.min
-1
. Toluene was used as flow-rate 
marker. Samples were filtered with a 0.2 m PTFE filter before analysis. The calibration 
curve was based on poly(methyl methacrylate) (PMMA) (range 1 850–1 916 000 g.mol-1) or 
poly(ethylene glycol) (PEG) (range 194–16 100 g.mol-1) standards from Agilent. The EcoSEC 
Analysis software enabled the determination of the number-average molar mass Mn, the 
weight-average molar mass Mw and the dispersity (Ð = Mw/Mn).  
SEC of degraded copolymers was performed at 30 °C on a system equipped with two 
columns from Agilent (PL-gel MIXED-D 300  7.5 mm, beads diameter 5 m; linear part 
400 to 4  105 g.mol-1) and a differential refractive index detector (Spectrasystem RI-150 
from Thermo Electron Corp.) using CHCl3 + 0.1 vol.% TFA as eluent, a Waters 515 HPLC 
Pump at a flow rate of 1 mL.min
-1
, and toluene was used as flow rate marker. Samples were 
filtered with a 0.2 m PTFE filter before analysis. The calibration curve was based on 
poly(methyl methacrylate) (PMMA) (range 1 850–1 916 000 g.mol-1) standards from Agilent, 
allowing Mn, Mw and Ð to be determined. 
Dynamic Light Scattering (DLS). Nanoparticles diameter (Dz) was measured by dynamic light 
scattering with a Nano ZS from Malvern with a detector angle of 173° (back scattering) at 
25 °C.  
3. Synthetic Procedures 
Synthesis of Im-MePEG2000. In a dry three-neck round bottom flask under Argon atmosphere, 
1,1’-carbonyldiimidazole (1.62 g, 0.010 mol, 2 equiv.) and 15 mL of anhydrous DCM were 
introduced. A solution of MePEG2000 (5 g, 0.005 mol, 1 equiv.) in 15 mL of anhydrous DCM 
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was added dropwise into the solution of CDI during 30 min. The reaction was carried out for 
6 h at room temperature under magnetic stirring. DCM was then evaporated under vacuum. 
Finally, the polymer was precipitated three times in diethyl ether and dried under high 
vacuum. Yield = 89 %. 
1
H NMR (300 MHz, CDCl3) δ 8.15 (s, 1H, N-CH=N), 7.44 (s, 1H, N-
CH=CH), 7.1 (s, 1H, N-CH=CH), 4.58-4.52 (m, 2H, N-COO-CH2), 3.63 (s, 174H, O-CH2-
CH2-O), 3.36 (s, 3H, O-CH3) (Figure S1). Mn = 2 300 g.mol
-1
. SEC (PEG calibration): Mn = 
1 800 g.mol
-1
. Ð = 1.03. 
Synthesis of PEG2000VE. In a dry round bottom flask under Argon atmosphere, Im-MePEG2000 
(3.0 g, 0.001 mol, 1 equiv.) was solubilized in 10 mL of anhydrous DCM. Then 
aminopropylvinylether (140 µL, 0.001 mol, 1 equiv.) was added under magnetic stirring. The 
reaction was carried out at 30 °C for 40 h. Then DCM was evaporated under vacuum. Finally, 
the polymer was precipitated three times in diethyl ether and dried under high vacuum. 
Yield = 82 %. 
1
H NMR (300 MHz, CDCl3) δ 6.45 (dd, J = 6.5 Hz, 1H, H2C=CH-O), 4.23-
4.18 (m, 2H, N-COO-CH2), 4.00 (dd, J = 4.0 Hz, 2H, H2C=CH-O), 3.89-3.54 (m, 2H, O-
CH2), 3.64 (s, 174H, O-CH2-CH2-O) 3.37 (s, 3H, O-CH3), 3.34-3.25 (m, 4H, CH2-CH2-NH) 
(Figure S2). Mn = 2 400 g.mol
-1
. SEC (PEG calibration): Mn = 1 850 g.mol
-1
. Ð = 1.02. 
Synthesis of poly(2-methylene-1,3-dioxepane)-co-(2-chloroethyl vinyl ether) (P(MDO-co-
CEVE)). A typical copolymerization procedure (fCEVE,0 = 0.1, expt. C1) is as follow. In a 7 
mL-vial, fitted with a rubber septum and a magnetic stirrer bar, a mixture of MDO (1.5 g, 
13.1 mmol), CEVE (155.6 mg, 1.5 mmol) and the initiator DEAB (113.2 mg, 0.4 mmol) was 
submitted to three freeze/thaw cycles and then backfilled with Argon. The mixture was then 
immersed in a preheated oil bath at 70 °C for 8 h. MDO conversion was calculated by 
1
H 
NMR, using the methylene protons of MDO (s, 3.5 ppm) and the CH2 protons in α-position to 
the ester group in the copolymer (t, 4.1 ppm). The copolymer was then precipitated once in 
cold cyclohexane and dried under high vacuum. Final composition of the purified copolymer 
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was calculated using 
1
H NMR (Figure S3) by comparing the signal at 4.0 ppm (MDO units, 
CH2 in α-position to the ester group) to the signal at 3.4-3.5 ppm (CEVE units, corresponding 
to 5 H of CEVE). The macromolecular characteristics (Mn and Ð) were determined by SEC 
(PMMA calibration) (Figure S4). The same procedure was followed by adapting the amount 
of reactants for fCEVE,0 = 0.2 (expt. C2) [MDO (1.5 g, 13.1 mmol), CEVE (350.1 mg, 3.3 
mmol) and DEAB (127.3 mg, 0.5 mmol)] and fCEVE,0 = 0.3 (expt. C3) [MDO (1.5 g, 13.1 
mmol), CEVE (600 mg, 5.6 mmol) and DEAB (145.5 mg, 0.6 mmol)].  
Synthesis of poly(2-methylene-1,3-dioxepane)-co-(tetra(ethylene glycol) methyl vinyl ether) 
(P(MDO-co-TEGVE)). A typical copolymerization procedure (fTEGVE,0 = 0.2, expt. T1) is as 
follow. In a 7 mL-vial, fitted with a rubber septum and a magnetic stirrer bar, a mixture of 
MDO (660.9 mg, 5.8 mmol), TEGVE (339.1 mg, 1.4 mmol) and the initiator DEAB (18.7 
mg, 0.07 mmol) was submitted to three freeze/thaw cycles and then backfilled with Argon. 
The mixture was then immersed in a preheated oil bath at 70 °C for 24 h. MDO conversion 
was calculated by 
1
H NMR, using the methylene protons of MDO (s, 3.5 ppm) and the CH2 
protons in α-position to the ester group in the copolymer (t, 4.1 ppm). The copolymer was 
then precipitated once in cold cyclohexane and dried under high vacuum. Final composition 
of pure copolymer was calculated using 
1
H NMR (Figure S5) by comparing the signal at 4.0 
ppm (MDO units, CH2 in α-position to the ester group) to the signal at 3.4-3.5 ppm (TEGVE 
units, terminal CH3). The macromolecular characteristics (Mn and Ð) were determined by 
SEC (PMMA calibration) (Figure S6). The same procedure was followed by adapting the 
amount of reactants for fTEGVE,0 = 0.25 (expt. T2) [MDO (593.7 mg, 5.2 mmol), TEGVE 
(406.3 mg, 1.7 mmol) and DEAB (17.9 mg, 0.07 mmol)].  
Synthesis of poly[(2-methyle-1,3-dioxepane)-co-(2-azidoethoxy)ethene] (P(MDO-co-N3VE). 
A typical procedure is as follow. In a 7-mL vial fitted with a rubber septum and a magnetic 
stirrer bar, a mixture of P(MDO-co-CEVE) (expt. C1, Mn = 12 600 g.mol
-1
, 100 mg, 7.9 x 10
-5
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mol), sodium azide (29 mg, 4.4 x 10
-4
 mol) in 5 mL of anhydrous DMF was degassed under 
stirring by argon bubbling for 15 min at room temperature. The mixture was then immersed in 
a preheated oil bath at 80 °C for 24 h. After, the mixture was allowed to cool to room 
temperature, THF was added and the resulting precipitated salts were filtered off twice using a 
0.2 µm PTFE syringe filter. The copolymer was dried under high vacuum. The same 
procedure was followed by adapting the amount of reactants: [expt. C2: Mn = 8 800 g.mol
-1
, 
100 mg, 1.1 x 10
-5 
mol), sodium azide (58 mg, 8.9 x 10
-4
 mol) in 5 mL of anhydrous DMF] 
and [expt. C3: Mn = 7 000 g.mol
-1
, 1.4 x 10
-5 
mol), sodium azide (86 mg, 1.32 x 10
-3
 mol) in 5 
mL of anhydrous DMF]. 
Synthesis of poly(2-methylene-1,3-dioxepane)-co-(PEG750VE) (P(MDO-co-PEG750VE)). A 
typical CuAAc procedure (expt. C1100) is as follow. In a 7 mL vial fitted with a rubber septum 
and a magnetic stirrer bar, a mixture of P(MDO-co-N3EVE) (Mn = 13 200 g.mol
-1
, 45 mg, 3.4 
x 10
-6
 mol), alkyne-MePEG750 (30 mg, 4.0 x 10
-5
 mol) in 2.5 mL of anhydrous DMF was 
degassed under stirring by argon bubbling for 30 min. Then CuBr (11.5 mg, 8.0 x 10
-5
 mol) 
was added and the solution was degassed further for 10 min. Finally, PMDETA (33 µL, 1.6 x 
10
-4
 mol) was added and the reaction mixture was stirred for 20 h at 40 °C. The reaction 
mixture was passed through a small column of neutral alumina to remove copper residues. 
Then DMF was evaporated under vacuum. Finally, the copolymer was precipitated once in a 
mixture of cyclohexane/diethyl ether 1:1 and dried under high vacuum before analysis by 
1
H 
NMR and SEC (Figure S7 and S8). The same procedure was followed by adapting the amount 
of reactants for (expt. C150) [P(MDO-co-N3EVE) (Mn = 13 200 g.mol
-1
, 45 mg, 3.4 x 10
-6
 
mol), alkyne-MePEG750 (15 mg, 2.0 x 10
-5
 mol), 2.5 mL of anhydrous DMF, CuBr (5.7 mg, 
4.0 x 10
-5
 mol) and PMDETA (16.7 µL, 8.0 x 10
-5
 mol)], (expt. C120) [P(MDO-co-N3EVE) 
(Mn = 13 200 g.mol
-1
, 150 mg, 1.1 x 10
-5
 mol), alkyne-MePEG750 (20 mg, 2.6 x 10
-5
 mol), 7.5 
mL of anhydrous DMF, CuBr (7.5 mg, 5.2 x 10
-5
 mol) and PMDETA (22 µL, 10.4 x 10
-5
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mol)], (expt. C2100) [P(MDO-co-N3EVE) (Mn = 10 900 g.mol
-1
, 100 mg, 9.2 x 10
-6
 mol), 
alkyne-MePEG750 (135 mg, 1.8 x 10
-4
 mol), 5 mL of anhydrous DMF, CuBr (51.6 mg, 3.6 x 
10
-4
 mol) and PMDETA (150 µL, 7.2 x 10
-4
 mol)], (expt. C250) [P(MDO-co-N3EVE) (Mn = 
10 900 g.mol
-1
, 45 mg, 4.1 x 10
-6
 mol), alkyne-MePEG750 (30 mg, 4.0 x 10
-5
 mol), 2.5 mL of 
anhydrous DMF, CuBr (11.5 mg, 8.0 x 10
-5
 mol) and PMDETA (33 µL, 1.6 x 10
-4
 mol)], 
(expt. C220) [P(MDO-co-N3EVE) (Mn = 10 900 g.mol
-1
, 80 mg, 7.3 x 10
-6
 mol), alkyne-
MePEG750 (21 mg, 2.8 x 10
-5
 mol), 4 mL of anhydrous DMF, CuBr (8.0 mg, 5.6 x 10
-5
 mol) 
and PMDETA (23.4 µL, 11.2 x 10
-5
 mol)], (expt. C3100) [P(MDO-co-N3EVE) (Mn = (9 300 
g.mol
-1
, 70 mg, 7.5 x 10
-6
 mol), alkyne-MePEG750 (142.5 mg, 1.9 x 10
-4
 mol), 3.5 mL of 
anhydrous DMF, CuBr (54.5 mg, 3.8 x 10
-4
 mol) and PMDETA (158 µL, 7.6 x 10
-4
 mol)], 
(expt. C350) [P(MDO-co-N3EVE) (Mn = 9 300 g.mol
-1
, 50 mg, 5.4 x 10
-6
 mol), alkyne-
MePEG750 (48.8 mg, 6.5 x 10
-5
 mol), 2.5 mL of anhydrous DMF, CuBr (18.6 mg, 1.3 x 10
-4
 
mol) and PMDETA (54 µL, 2.6 x 10
-4
 mol)] and (expt. C320) [P(MDO-co-N3EVE) (Mn = 
9 300 g.mol
-1
, 100 mg, 1.0 x 10
-5
 mol), alkyne-MePEG750 (40 mg, 5.3 x 10
-5
 mol), 5 mL of 
anhydrous DMF, CuBr (14.3 mg, 1.0 x 10
-4
 mol) and PMDETA (42 µL, 2.0 x 10
-4
 mol)]. 
Synthesis of poly(2-methylene-1,3-dioxepane)-co-(VE-PEG2000) (P(MDO-co-PEG2000VE)). In 
a 7 mL-vial, fitted with a rubber septum and a magnetic stirrer bar, a mixture of MDO 
(379 mg, 3.3 mmol), PEG2000VE (371 mg, 0.18 mmol) and the initiator DEAB (27 mg, 
0.1 mmol) was degassed by Argon bubbling for 30 min. The mixture was then immersed in a 
preheated oil bath at 70 °C. MDO conversion was calculated by 
1
H NMR spectroscopy using 
the methylene protons of MDO (s, 3.5 ppm) and the CH2 protons in α-position to the ester 
group in the copolymer (t, 4.1 ppm). The copolymer was precipitated once in a cold mixture 
of cyclohexane/diethyl ether 1:1 and dried under vacuum. The resulting solid was solubilized 
in distillate water (1.7 mg.mL
-1
) and this solution was dialysed over a 6-8 kD cut-off 
membrane for 8 days. Finally, the solution was freeze-dried for 24 h. Final composition of 
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purified copolymer was calculated using 
1
H NMR (Figure S9) by comparing the signal at 4.0 
ppm (MDO units, CH2 in α-position to the ester group) to the signal at 3.4 ppm (PEG2000VE 
units, methoxy protons). The macromolecular characteristics (Mn and Ð) were determined by 
SEC (PMMA calibration) (Figure S10). 
Synthesis of poly(2-methylene-1,3-dioxepane) (PMDO). In a 7 mL-vial, fitted with a rubber 
septum and a magnetic stirrer bar, a mixture of MDO (362.4 mg, 3.2 mmol) and the initiator 
DEAB (25.8 mg, 0.1 mmol) was degassed by Argon bubbling for 30 min. The mixture was 
then immersed in a preheated oil bath at 70 °C. After 1 h, the polymer was precipitated once 
in cold cyclohexane and dried under vacuum. Conversion in MDO after 1 h = 20 %. SEC 
(PMMA calibration): Mn = 11 400 g.mol
-1
. Ð = 1.4.  
4. Nanoparticles Preparation 
Nanoparticles were prepared by the nanoprecipitation technique.
32
 For P(MDO-co-CEVE) 
(C1-C3), 2.0 mg of copolymer were dissolved in 670 µL of THF and this solution was added 
dropwise to 2 mL of a solution of Pluronic
®
 (1 wt.% in MilliQ water) under stirring. THF was 
then evaporated at room temperature using a Rotavapor. Intensity-averaged diameter (Dz) 
measurements were carried out in triplicate. The same procedure was applied for P(MDO-co-
TEGVE) (T1 and T2) and copolymers functionalized by CuAAC P(MDO-co-PEG750VE) 
(C120, C150, C220). Briefly, 2.0 mg of copolymer was dissolved in 670 µL of THF and this 
solution was added dropwise to 2 mL of MilliQ water under stirring. Similarly, for P(MDO-
co-PEG2000VE) with 45 wt.% of PMDO, 2.7 mg of P(MDO-co-PEG2000VE) and 2.6 mg of 
PMDO were dissolved in 1.8 mL of THF. This solution was added dropwise to 4.8 mL of 
MilliQ water under stirring. For P(MDO-co-PEG2000VE) with 80 wt.% of PMDO, 1.5 mg of 
P(MDO-co-PEG2000VE) and 6.5 mg of PMDO were dissolved in THF and this solution was 
added dropwise in 8 mL of MilliQ water under stirring. 
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For stability study, the different samples were either let in water or diluted in PBS to 
reach a final concentration of 0.5 mg.mL
-1
. Samples were kept at 4 °C and let warm to room 
temperature before each measurement. 
 
5. Degradation Experiments 
Accelerated Degradation. In a 7 mL-vial, 50 mg of copolymer was dissolved in 2.5 mL of 
THF. After solubilization, 2.5 mL of sodium hydroxide solution (NaOH, 1%) in methanol 
was added. The mixture was stirred at room temperature. Samples (1 mL) were periodically 
taken, immediately dried under high vacuum and 2 mL of chloroform was added. The organic 
solution was washed three time with an aqueous solution of HCl 1M, then filtered twice with 
0.2 µm PTFE filter to remove the salts. Solvent was then removed under reduced pressure and 
degradation products were analysed by SEC (PMMA calibration). 
Long-Term Hydrolytic Degradation. The following method was applied for each kinetic point 
(i.e., 3, 6, 9 and 12 months). In a 7 mL-vial, 20 mg of copolymer was poured into 2 mL of 
PBS 1X and mechanically stirred in an orbital shaker at 37 °C. At the kinetic given point, the 
vial was withdrawn from the shaker, and the content was freeze-dried. 2 mL of chloroform 
was then added, allowing removal of buffer salts by filtration. Finally, the solvent was 
removed under reduced pressure, and the degradation products were analysed by SEC 
(PMMA calibration). 
Enzymatic Degradation. The following method was applied for each kinetic point (i.e., 24 and 
48 h). In a 7 mL-vial, 20 mg of copolymer was poured into 2 mL of PBS 1X and 
mechanically stirred in an orbital shaker at 37 °C. Briefly, 20 mg of copolymer was 
solubilized in 500 µL of THF and added dropwise to 2 mL of PBS. THF was evaporated and 
lipase from Candida antarctica (100 U.mL
-1
) was added to the mixture. At the given point the 
vial was withdrawn from the shaker, and the content was freeze dried. 2 mL of chloroform 
14 
 
was then added, allowing removal of buffer salt and immobilized enzymes by filtration. 
Finally, the solvent was removed under reduced pressure, and the degradation products were 
analysed by SEC (PMMA calibration). 
 
6. Cytotoxicity Evaluation 
Cell lines and cell culture. Human endothelial umbilical vein cells (HUVEC) and murine 
macrophage-monocyte cells (J774.A1) were maintained as recommended. HUVEC cells were 
grown in Dulbecco’s Modified Eagle Medium (DMEM) high glucose supplemented with 10 
% Foetal Bovine Serum (FBS), penicillin (100 U.mL
-1
) and streptomycin (100 U.mL
-1
). 
J774.A1 cells were grown in Roswell Park Memorial Institute medium (RPMI) 1640 
supplemented with 10 % heat-inactivated (56 °C, 30 min) FBS, penicillin (100 U.mL
-1
) and 
streptomycin (100 U.mL
-1
). Cells were maintained in a humid atmosphere at 37 °C with 
5 % CO2. 
Cytotoxicity study. In vitro cytotoxicity activity of the copolymers was evaluated on the two 
cell lines using 3-[4,5-dimethylthiazol-2-yl]-3,5-diphenyltetrazolium bromide (MTT) test. 
Cells were seeded in 100 µL of growth medium (8 cells.mL-1) in 96-well microliter 
plates and preincubated for 24 h. After appropriate dilutions, 100 µL of copolymer solution in 
cell culture medium was added over the cells and incubated for 72 h. At the end of incubation 
period, 20 µL of MTT solution (5 mg.mL
-1
 in PBS) were then added to each well. The plates 
were incubated 1.5 h at 37 °C and the medium was removed. 200 µL of DMSO was then 
added to each well to dissolve the precipitates. Absorbance was measured at 570 nm using a 
plate reader (Metertech Σ 960, Fisher Bioblock, Illkirch, France). The percentage of surviving 
cells was calculated as the absorbance ratio of treated cells to untreated cells. All experiments 
were set up in sextuplicate to determine means and SD. 
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Results and Discussion 
1. Rationale of the copolymer synthesis  
A small library of copolymers was obtained by conventional radical copolymerization 
between 2-methylene-1,3-dioxepane (MDO) and vinyl ether derivatives of different nature. 
The idea was to prepare copolymers of variable aqueous solubility (i.e., hydrophobic, 
amphiphilic or water-soluble) and to formulate them into nanoparticles (Figure 2). To obtain 
stable nanoparticles and ensure efficient colloidal stability, hydrophobic copolymers were 
formulated in the presence of surfactants (Figure 2a, Path 1) conversely to amphiphilic 
copolymers (surfactant-free formulation, Figure 2a, Path 2 and Figure 2b), whereas water-
soluble copolymers were blended with hydrophobic PMDO prior formulation without 
surfactant (Figure 2c). These three different procedures have been routinely employed with 
polyesters to prepare biodegradable nanoparticles for drug delivery. Indeed, PLA can be 
formulated in the presence of (macro)molecular surfactants such as sodium cholate
33
 or 
Pluronics,
34
 whereas PLA-b-PEG diblock copolymer can be, depending on its amphiphilicity, 
either directly formulated into nanoparticles
35
 or blended with PLA prior the formulation 
step.
36
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Figure 2. Synthesis of: (a) P(MDO-co-CEVE) copolymers and nanoprecipitation in the 
presence of Pluronic surfactants (Path 1), or P(MDO-co-N3VE) copolymers by azidation of 
P(MDO-co-CEVE) followed by grafting of alkyne-PEG750 by CuAAC and nanoprecipitation 
(Path 2); (b) P(MDO-co-TEGVE) and nanoprecipitation and (c) P(MDO-co-PEG2000VE) and 
co-nanoprecipitation with PMDO.   
 
2. Copolymer synthesis 
As for hydrophobic copolymers, 2-chloroethyl vinyl ether (CEVE) was copolymerized by 
rROP with different initial molar fractions of MDO (fMDO,0 = 0.9–0.7) at 70 °C in bulk with 
DEAB as the initiator to give P(MDO-co-CEVE) copolymers (C1–C3, Table 1 and Figure 2a, 
Path 1). Final Mn after 8 h of copolymerization was ~ 9 000 g.mol
-1
 with broad molar mass 
distribution (Ð ≥ 2) in agreement with the free-radical process. As expected from the 
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favourable reactivity ratios,
30
 final molar fractions of MDO, FMDO, were in excellent 
agreement with the corresponding fMDO,0 values, assessing the nearly ideal copolymerization. 
 To design amphiphilic P(MDO-co-VE) copolymers, the idea was to incorporate PEG 
segments in the copolymer structure. To this end, two different routes were explored: (i) the 
direct copolymerization between MDO and tetra(ethylene glycol) methyl vinyl ether 
(TEGVE) (Figure 2b) and (ii) the post-functionalization of P(MDO-co-N3VE) with alkyne-
PEG750 by copper(I)-catalyzed azide alkyne cycloaddition (CuAAC)
35,37,38
 (Figure 2a, Path 2). 
Copolymerization between MDO and TEGVE was performed under similar experimental 
conditions with fMDO,0 = 0.80 and 0.75 and resulted in P(MDO-co-TEGVE) copolymers (T1 
and T2, Table 1) with Mn = 9200 and 7100 g.mol
-1
, dispersities around 1.5 and a fairly good 
agreement between fMDO,0 and FMDO values (0.76 and 0.66, respectively). As for the post-
functionalization approach, P(MDO-co-CEVE) C1–C3 were first reacted at 80 °C for 24 h 
with sodium azide to quantitatively replace chlorine atoms by azide moieties, leading to 
P(MDO-co-N3VE) copolymers. Subsequently, CuAAC with CuBr/PMDETA as the catalytic 
system was performed with alkyne-PEG750 in DMF at 40 °C for 20 h by targeting variable 
coupling ratios (i.e., 20, 50 and 100 mol.% with respect to the total amount of azide groups), 
resulting in nine different P(MDO-co-PEG750VE) copolymers (Cx20, Cx50 and Cx100, with x = 
1–3, see Table 1). 
A water-soluble copolymer was also obtained by direct copolymerization between 
MDO and a PEG2000VE macromonomer (fMDO,0 = 0.95) for 4 h under otherwise identical 
experimental conditions (P1, Table 1 and Figure 2c). PEG2000VE was synthesized by coupling 
aminopropylvinyl ether with MePEG2000 through CDI coupling.
39,40
 The resulting P(MDO-co-
PEG2000VE) was purified by dialysis to remove unreacted monomer and gave Mn = 13 000 
g.mol
-1
, Đ = 1.4 and a final molar fraction of MDO of 0.76.  
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Table 1. Experimental Conditions and Macromolecular Characteristics of the Different 
Copolymers Synthesized in this Study.
 
Expt.  VE f
MDO,0
a  F
MDO
b F
PEG
c 
MDO conv. 
(%)
d
 / time 
(h) 
M
n, exp.
  
(g.mol
-1
)
e 
Ð
 e 
C1 CEVE 0.90 0.90  70 / 8 12 600 3.30 
C1100 PEG750VE - - 0.09   4 200 1.53 
C150 PEG750VE - - 0.05  13 800 1.30 
C120 PEG750VE - - 0.02  8 500 1.80 
C2 CEVE 0.80 0.83  46 / 8 8 800 2.45 
C2100 PEG750VE - - 0.17  5 500 1.50 
C250 PEG750VE - - 0.10  7 800 1.12 
C220 PEG750VE - - 0.06  9 000 1.09 
C3 CEVE 0.70 0.73  18 / 8 7 000 1.97 
C3100 PEG750VE - - 0.27  2 800 1.55 
C350 PEG750VE - - 0.17  11 300 1.30 
C320 PEG750VE - - 0.07  9 500 1.10 
T1 TEGVE 0.80 0.76  49 / 24 9 200 1.50 
T2 TEGVE 0.75 0.66  35 / 24 7 100 1.44 
P1 PEG2000VE 0.95 0.76  34 / 4 13 000 1.40 
a 
Initial molar fraction of MDO in the monomer feed. 
b
 Molar fraction of MDO in the purified copolymer 
determined by 
1
H NMR. 
c
 Determined by 
1
H NMR by assessing the coupling yield using the CH2 in α-position to 
the triazole ring (4.4 ppm) and the CH2 in α-position to ester group in the copolymer (4.1 ppm).
30
 
d
 Calculated by 
1
H NMR before purification. 
e
 Determined by SEC in chloroform with PMMA standards. 
3. Formulation and colloidal characteristics 
Hydrophobic P(MDO-co-CEVE) copolymers C1–C3 were formulated into nanoparticles in 
the presence of surfactants using the nanoprecipitation technique (Figure 2a, Path 1).
32
 As 
surfactants, we selected the Pluronic family as they are widely employed
41
 for drug delivery 
purposes and also because having a PEG-based coating at the surface of the nanoparticles 
could be advantageous in terms of biocompatibility and stealth properties.
42-46
 Pluronics are 
triblock copolymers, with a hydrophobic central block of poly(propylene oxide) (PPO), two 
hydrophilic external blocks of poly(ethylene oxide) (PEO), and whose solution/colloidal 
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properties can be finely tuned by changing the PPO and PEO block lengths.
45
 Five Pluronics 
were tested: L64, F68, F108, P123 and F127; giving three different lengths of PPO and five 
different lengths of PEO (Table S1). P(MDO-co-CEVE) nanoparticles were formulated at 1 
mg.mL
-1
 in presence of 1 wt.% of each Pluronic. 
Overall, all formulations gave nanoparticle suspensions with intensity-averaged 
diameters (Dz) ranging from 175 to 360 nm and particle size distributions between 0.13 and 
0.25 (Table 2 and Figure S11a-c). No noticeable influence of the copolymer composition 
neither of the length of the PPO block on the nanoparticle size was observed. However, 
increasing: (i) the molar fraction of CEVE whatever the surfactant or (ii) the weight 
percentage of the PEO for a fixed PPO block length, resulted in a noticeable increase of Dz. 
For instance, average Dz were 200, 230 and 240 nm for nanoparticles C1, C2 and C3, 
respectively. Interestingly, whereas nanoparticles stabilized by Pluronic F68 and F108 gave, 
on average, higher Dz values than those stabilized by Pluronic L64, P123 or F127, their 
polydispersity indexes were among the lowest (~0.16).  
 
Table 2. Colloidal Characteristics of P(MDO-co-CEVE) Nanoparticles Stabilized by Pluronic 
Surfactants.
a 
 C1 C2 C3 
Pluronic 
Dz
 
 
(nm) 
PSD 
Dz
 
 
(nm) 
PSD 
Dz
 
 
(nm) 
PSD 
L64 200 0.17 210 0.20 215 0.13 
F68 230 0.20 250 0.17 360 0.12 
F108 200 0.17 260 0.22 230 0.13 
P123 175 0.25 200 0.24 180 0.21 
F127 210 0.22 210 0.19 200 0.16 
a
 Determined by DLS. 
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Given copolymers T1 and T2 contained hydrophilic TEG pending units (24 and 34 mol.%, 
respectively), and thus a certain amphiphilicity, they were nanoprecipitated into nanoparticles 
(1 mg.mL
-1
) without any additional surfactant (Figure 2b). Nanoparticles of Dz = 220 nm 
(PSD = 0.14) and 170 nm (PSD = 0.16), respectively, were successfully formed (Figure 
S11d). Note that T2, which contained the highest amount of TEGVE units, led to 
nanoparticles with the best colloidal properties (i.e., lowest Dz and PSD).  
Similarly, P(MDO-co-PEG750VE) copolymers obtained by CuAAC between P(MDO-
co-N3VE) and alkyne-PEG750 were also directly nanoprecipitated in aqueous solution without 
any surfactant (Figure 2a, Path 2). Whereas copolymers with 100 % coupling with 
alkynePEG750 (Cx100) were totally water soluble, best nanoparticle formulations were obtained 
for intermediate coupling yields and/or low PEG750 contents (< 0.1 mol.%), with Dz in the 
130–150 nm range and very narrow PSD (0.06–0.15) indicating efficient stabilization and 
promising colloidal features for use in drug delivery applications (Table 3 and Figure S11e). 
 
Table 3. Colloidal Properties of Nanoparticles Obtained by CuAAC between P(MDO-co-
N3VE) and Alkyne-PEG750.
a
 
Expt.  
CuAAC coupling ratio 
(%) 
F
PEG750
b Dz 
(nm) 
PSD 
C120 20 0.02 130 0.11 
C150 50 0.05 145 0.06 
C220 20 0.06 150 0.15 
a 
Determined by DLS. 
b
 Determined by 
1
H NMR spectroscopy. 
Considering its too high water-solubility, likely because of the long PEG2000 chains, P(MDO-
co-PEG2000VE) P1 was fully water soluble and did not form nanoparticles by 
nanoprecipitation. However, successful formation of nanoparticles was obtained by 
nanoprecipitation of a mixture of P1 and PMDO, acting as the main constituent of the 
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nanoparticle core (Figure 2c). By tuning the weight percentage of PMDO, the nanoparticle 
size was efficiently modified (Figure S11f). Indeed, with 80 wt.% PMDO, Dz = 290 nm (PSD 
= 0.22) whereas with 45 wt.% PMDO to 45 %, Dz = 160 nm (PSD = 0.12), the latter being in 
the good size window for drug delivery purposes.  
Colloidal stability of a selection of nanoparticles was then assessed over a period of 14 
days. Overall, no major change in size was observed for P(MDO-co-CEVE) nanoparticles 
except for nanoparticles C1–C3 stabilized by Pluronic F68, whose diameters significantly 
increased (Figure 3a-c). As for nanoparticles T1 and T2, the average diameter and the PSD 
stayed relatively constant over time (Figure 3d) and nanoparticles were perfectly stable up to 
7 days before a few amounts of precipitate started to form, likely because of too short EO 
chain lengths to confer efficient stabilization in the long run. Therefore, these nanoparticles 
would likely exhibit enhanced colloidal stability if copolymers T1 and T2 would be 
formulated in the presence of surfactant. As for P(MDO-co-PEG750VE) nanoparticles, they 
gave very high colloidal stability as the average diameter stayed nearly constant up to 6 
months with a still narrow particle size distribution (PSD = 0.07). P(MDO-co-
PEG2000VE)/PMDO nanoparticles also exhibit high colloidal stability as shown by the 
constant diameters and the low PSD over time, especially for the formulation obtained with 
45 wt.% PMDO, which also exhibited stability in PBS at least up to 11 days (Figure 3e,f). 
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Figure 3. Evolution with time of the average diameter (Dz) and the particle size distribution (PSD) of P(MDO-co-VE) nanoparticles. (a) P(MDO-co-CEVE) 
(C1) stabilized by Pluronics. (b) P(MDO-co-CEVE) (C2) stabilized by Pluronics. (c) P(MDO-co-CEVE) (C3) stabilized by Pluronics. (d) P(MDO-co-TEGVE) 
(T1 and T2) in water. (e) P(MDO-co-PEG2000VE) (P1) co-nanoprecipitated with PMDO in water. (f) Picture of nanoparticles obtained by co-nanoprecipitation 
of P(MDO-co-PEG2000VE) P1 depending on the amount of PMDO. 
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4. Degradation study 
Assessing degradation of a new materials intended to be used for biomedical applications is of 
prime importance. Degradation was therefore comprehensively studied under three different 
conditions: (i) hydrolytic degradation under accelerated conditions (1 wt.% NaOH); (ii) 
hydrolytic degradation under physiological conditions (PBS 1X, pH 7.4, 37 °C) and (iii) 
enzymatic degradation in presence of lipases (Candida antarctica).  
Hydrolytic degradation under accelerated conditions was conducted on P(MDO-co-
CEVE) (C1–C3) and P(MDO-co-TEGVE) (T1 and T2). Even though these conditions poorly 
reflect the biological environment, they are useful and routinely used to confirm the presence 
of labile groups in the copolymer backbone. The degradation was followed for 1 h at room 
temperature in THF with 1 wt. % NaOH in methanol. In all cases, clear shifts of SEC 
chromatograms toward very low Mn (560–680 g.mol
-1
 for C1–C3 and 970–980 g.mol-1 for T1 
and T2) were obtained (Figure S12, 4a and Table 4). Degradations ranged from 86 to 96% 
and were influenced by the amount of MDO in the copolymer; the higher FMDO, the greater 
the Mn decrease. Such nearly complete degradations were the result of the high molar 
fractions of MDO in the copolymers (FMDO = 0.66–0.90). This was made possible by the 
quasi-random copolymerization of CKA and VE derivatives, as opposed to copolymerizations 
between CKA and methacrylic esters, whose unfavorable reactivity ratios lead to copolymers 
composed of isolated CKA units and consecutive methacrylic ester units, the average chain 
length of which is governed by FCKA. 
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Table 4. Features of the Accelerated Hydrolytic Degradation of the Different P(MDO-co-
CEVE) and P(MDO-co-TEGVE) Copolymers.
a 
expt. VE FMDO
b 
theo. M
n,∞
c
 
(g.mol
-1
) 
exp. M
n
 d 
(g.mol
-1
) 
M
n
  
decrease
 e
  
(%) 
M
n,∞
 f 
(g.mol
-1
) 
t1/2
f 
(min) 
initial deg. rate 
(g.mol
-1
.min
-1
)
f
 
C1 CEVE 0.90 330 560 -96 690 1.31 6 300 
C2 CEVE 0.80 330 630 -93 820 1.21 4 600 
C3 CEVE 0.70 330 680 -90 950 1.52 2 800 
T1 TEGVE 0.76 520 970 -90 1 000 1.91 3 000 
T2 TEGVE 0.66 520 980 -86 1 100 1.31 3 200 
a 
Degradation was performed for 1 h at room temperature in THF with 1% NaOH in methanol. 
b 
Molar fraction 
of MDO in the copolymer determined by 
1
H NMR. 
c 
Calculated according to: n × MWVE + MWMDO with n = 2.
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d
 Determined by SEC. 
e
 Mn decrease after accelerated hydrolytic degradation calculated according to (exp. Mn – 
Mn,0)/Mn,0. 
f
 Extracted from exponential decay fit. 
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Figure 4. Evolution of the number-average molar mass, Mn, with time during degradation of 
P(MDO-co-CEVE) (C1–C3) and P(MDO-co-TEGVE) (T1, T2) copolymers under different 
conditions. (a) Accelerated hydrolytic degradation (THF with 1 % NaOH in methanol). Insert: 
zoom in between -70 and -100 % for the Y-axis. (b) Long-term hydrolytic degradation (PBS 
1x, pH = 7.4, 37 °C). (c) Enzymatic degradation (PBS 1x, pH = 7.4, with lipases (Candida 
antarctica) at 37 °C). ●, C1 (FMDO = 0.90); ■, C2 (FMDO = 0.83); ▲, C3 (FMDO = 0.73); ♦, T1 
(FMDO = 0.76); , T2 (FMDO = 0.66). Dashed lines are only guides for the eye. 
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To further characterize these new degradable copolymers, an exponential decay fit was then 
applied to each degradation kinetics to determine the Mn reached at equilibrium (Mn,∞), the 
half-life time (t1/2) and the initial degradation rate (Figure S13 and Table 4). While the 
different Mn,∞ values were very similar to their experimental counterparts, indicating 
equilibrium of the degradation reaction, t1/2 values as low as ~1–2 min and initial degradation 
rate ranging from 3000 to 6300 g.mol
-1
.min
-1
 were obtained. These values may be important 
for potential benchmarking between different degradable materials by selecting the most 
appropriate ones for the desired applications. 
To better mimic the physiological conditions in which these materials are intended to 
be used, P(MDO-co-CEVE) (C1–C3) and P(MDO-co-TEGVE) (T1, T2) copolymers were 
subjected to long-term hydrolytic degradation in PBS (1X, pH 7.4) under thermostated orbital 
shaking at 150 rpm and 37 °C. The Mn evolution was monitored by SEC by withdrawing 
samples at given time points (i.e., 3, 6, 9 and 12 months). As for the accelerated hydrolytic 
degradation, a shift toward lower Mn was observed in each case (Figure S14), although on a 
much longer time frame as expected, with a similar Mn decrease vs. FMDO trend (Figure 4b). 
Interestingly, TEGVE-based copolymers T1 and T2 led to a faster degradation rate with a Mn 
decrease of ~60-70 % after 12 months, whereas CEVE-based copolymers C1–C3 degraded 
much slower with a Mn decrease of ~20 % after 9 months (Figure 4b). This result is explained 
by a difference of solubility from the two series of copolymers as C1–C3 are hydrophobic 
thus preventing efficient solvation of ester groups and their rapid hydrolysis, whereas TEGVE 
units from T1 and T2 provided enough hydrophilicity to allow good solvation of the 
copolymers and thus efficient cleavage of ester groups. Given degradation is still on going 
after 9-12 months, as shown by the negative slope of the degradation kinetics (Figure 4b), 
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much lower Mn, similar to those obtained under accelerated conditions, are likely to be 
obtained if the degradation is prolonged for a longer period of time. 
From a comparative point of view with traditional polyesters, P(MDO-co-CEVE) C1–
C3 led to similar degradation patterns than polycaprolactone (PCL) under identical 
degradation conditions, for which a Mn decrease of ~20 % after 3 months
26
 and of ~30 % after 
9 months
48
 has been reported. This is likely the result of the structural similarity between PCL 
and PCL-like P(MDO-co-CEVE) copolymers, especially given their high MDO contents. As 
expected from their much higher water-solubility, copolymers T1 and T2 gave a faster 
degradation in between that of PCL and polylactide (PLA), whose Mn decrease is ~ 80 % after 
9 months and nearly complete after 12 months.
48,49
  
This is a very interesting feature of this copolymerization system as it is possible to 
tune/accelerate the degradation rate of a PCL-like copolymer obtained by a radical 
mechanism by: (i) adjusting the amount of MDO in the copolymer and (ii) incorporation of 
hydrophilic VE units. 
Evolution of pH with time was also monitored during long-term hydrolytic 
degradation. Whereas P(MDO-co-TEGVE) copolymers led to a decrease of pH down to ~5 
after 12 months, similarly to PLA and PLGA,
48,50,51
 P(MDO-co-CEVE) copolymers led to 
nearly stable pH around 6.8 (Figure 5), like PCL.
48
 3 
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Figure 5. Evolution of pH with time during long-term hydrolytic degradation in PBS (1X, 
pH = 7.4, 37 °C) of MDO-based copolymers. ●, C1 (FMDO = 0.90); ■, C2 (FMDO = 0.83); ▲, 
C3 (FMDO = 0.73); ♦, T1 (FMDO = 0.76); , T2 (FMDO = 0.66). 
Developing new hydrolytically degradable, vinyl materials is already a promising step 
towards their safe use in biomedical applications, especially because it is considered as the 
main degradation mechanism of aliphatic polyesters
52
 in vivo. However, making them also 
susceptible to enzymatic degradation
53
 would also be advantageous as two distinct 
degradation pathways could be used, thus ensuring their excretion from the body after 
administration. P(MDO-co-CEVE) (C1–C3) and P(MDO-co-TEGVE) (T1, T2) copolymers 
were incubated in the presence of lipases from Candida antarctica, a subclass of 
esterases,
27,54,55
 in PBS at 37 °C and evolution of Mn was monitored over time. In all cases, 
SEC chromatograms exhibited clear shifts toward low Mn (Figure S15) and final Mn were as 
low as 320–480 g.mol-1 for C1–C3 and 400–430 g.mol-1 for T1 and T2 (Figure 4c and Table 
5). These results accounted for a (nearly) complete degradation in the presence of enzyme 
whatever the copolymer used as decrease in Mn was in the 92–97 % range. By plotting the 
evolution of Mn with time and applying an exponential decay fit, Mn,∞, the half-life time (t1/2) 
and initial degradation rate were determined (Figure S16 and Table 5). Interestingly, t1/2 
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values of T1 and T2 were similar than those for C1–C3, despite their different 
nature/solubility. 
 
Table 5. Features of the Enzymatic Degradation of P(MDO-co-CEVE) and P(MDO-co-
TEGVE) Copolymers.
a 
expt. VE FMDO
b 
theo. M
n,∞
c
 
(g.mol
-1
) 
exp. M
n
 d 
(g.mol
-1
) 
M
n
 decrease
e
 
(%) 
M
n,∞
f
  
(g.mol
-1
)
e
 
t1/2
f 
(h) 
initial deg. rate 
(g.mol
-1
.min
-1
)
 f
 
C1 CEVE 0.90 330 320 -97 320 3.9 2 400 
C2 CEVE 0.80 330 420 -95 200 6.3 1 000 
C3 CEVE 0.70 330 580 -92 500 4.4 1 100 
T1 TEGVE 0.76 520 410 -96 500 2.5 1 800 
T2 TEGVE 0.66 520 440 -94 550 3.3 1 200 
a
 Degradation was performed for 48 h at 37 °C in PBS (pH = 7.4) in the presence of Candida antarctica. 
b
 Molar 
fraction of MDO in the copolymer determined by 
1
H NMR. 
c 
Calculated according to: n × MWVE + MWMDO with 
n = 2.
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d
 Determined by SEC. 
e 
Mn decrease after enzymatic degradation calculated according to (exp. Mn – 
Mn,0)/Mn,0. 
f
 Extracted from exponential decay fit. 
Quantitative enzymatic degradation of P(MDO-co-VE) copolymers represented a very 
important result. Indeed, enzymatic degradation of copolymers obtained by rROP of 
methacrylic esters and CKA, one of the most studied radical ring-opening copolymerization 
systems so far, is often moderate likely because of the rather low amount of CKA units in the 
copolymer backbone (although impact of the CKA structure, in terms of steric hindrance and 
hydrophobicity, cannot not be ruled out). For instance, P(OEGMA-co-MPDL) copolymers 
(FMPDL = 0.27) incubated with Candida antarctica in 0.1 M PBS at 37 °C for 1 week led to a 
Mn decrease of ~15%, whereas no degradation was observed with P(MMA-co-MPDL) 
copolymers.
48
 Also, P(MEO2MA-co-OEGMA-co-BMDO) terpolymers subjected to identical 
degradation conditions were not entirely degraded after 24 h (only ~40% of the main-chain 
ester groups were hydrolysed).
19
 Similarly, copolymers based on MDO and PEGMA (FMDO = 
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0.5) incubated in the presence of lipase from Pseudomonas cepacia led to uncompleted 
degradation (not quantified) even after 5 days at 37 °C.
28
 
 
5. Cytotoxicity study 
Biomedical applications require the use of non-cytotoxic materials. In this context, 
preliminary in vitro cytotoxicity tests were performed on two different cell lines: human 
umbilical vein endothelial cells (HUVEC) and murine macrophages (J774.A1). These two cell 
lines are representative of important cell types in mammalian organisms. HUVEC are cells 
that line blood and lymphatic vessels and are among the first cells nanoparticles could 
encounter in the case of an intravenous injection. Therefore, this cell line is a relevant cell 
model for investigation preliminary cytotoxicity.
56,57
 J774.A1 are macrophages that are highly 
involved in phagocytosis. Moreover, macrophages are the first line of defence in the immune 
response machinery. Hence, such a cell line is also relevant when investigating potential 
cytotoxicity of a synthetic materials intended to be administered intravenously. 
MTT assays were performed to evaluate in vitro cytotoxicity of the nanoparticles with 
a maximal concentration of 0.1 mg.mL
-1
; that is ~5–10 times more than IC50 values reported 
for poly(alkyl cyanoacrylate) nanoparticles,
58-60
 which represent so far the only example of 
biodegradable vinyl nanoparticles that reached advanced clinical trials (Phase III) for 
anticancer therapy.
61-63,64
 PEGylated nanoparticles T1, T2, C120, C150 and C220 were 
subjected to MTT assays as PEGylation resulting from grafted PEG chains to 
polymers/nanoparticles is preferable to surface adsorbed PEG polymers that can desorb, 
leaving holes in surface coverage where plasmatic proteins can bind.
65
 On HUVEC cells, 
except for nanoparticles C120 at 0.1 mg.mL
-1
, cell viabilities were >75% at 0.01 and 0.1 
mg.mL
-1
 for all copolymers tested (Figure 6a,b). The highest cell viabilities at 0.1 mg.mL
-1
 
were obtained for nanoparticles made of copolymer C150 and C220, with values ~84%. Given 
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their high cell viabilities, C150 and C220 nanoparticles were also tested on J774.A1 cells, 
leading to high cell viabilities ranging from 75 to 96% (Figure 6c).  
 
 
Figure 6. Cell viability (MTT assay) after incubation of: (a) HUVEC cells with P(MDO-co-
TEGVE) nanoparticles T1 and T2 at 0.01 and 0.1 mg.mL
-1
; (b) HUVEC cells with P(MDO-
co-PEG750VE) nanoparticles C120, C150 and C220 at 0.1 mg.mL
-1
 and (c) J774.A1 with 
P(MDO-co-PEG750VE) nanoparticles C120, C150 and C220 at 0.1 mg.mL
-1
. Results were 
expressed as percentages of absorption of treated cells (±SD) in comparison with the values 
obtained from untreated control cells. 
 
Given the water-solubility of P(MDO-co-PEG2000VE) (P1) and its use as efficient stabilizer 
for the formulation of PMDO nanoparticles, as shown earlier in this work, it was also tested 
for its potential cytotoxicity on HUVEC and J774.A1 cells up to very high concentrations (1 
mg.mL
-1
) (Figure 7). The purpose of using such a very high concentration was only to 
overexpress any cytotoxic effect that could arise from the nature of the polymer and/or its 
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degradation products. From the results, P1 led to high cell viabilities from 75 to 100% up to 
0.2 mg.mL
-1
 on both cell lines. Whereas significant cytotoxicity appeared at 0.5 mg.mL
-1
 on 
J774.A1 cells, cell viabilities stayed constant at ~75% on HUVEC cells up to a concentration 
as high as 1 mg.mL
-1
, thus assessing the safe use of this copolymer for biomedical 
applications and especially as PEG-based coating for hydrophobic polymer nanoparticles.  
 
 
Figure 7. Cell viability (MTT assay) after incubation of HUVEC and J774.A1 cells at 
increasing concentrations from 0.01 to 1 mg.mL
-1
 of P(MDO-co-PEG2000VE) copolymer (P1). 
Results were expressed as percentages of absorption of treated cells (± SD) in comparison 
with the values obtained from untreated control cells. 
 
 
Conclusion 
The nearly ideal free-radical ring-opening copolymerization between MDO and VE 
derivatives was employed to synthesize a small library of degradable vinyl copolymers with 
Mn ~10 kg.mol
-1
, high MDO molar fractions (FMDO = 0.7–0.9) and whose aqueous solubility 
was varied by changing the nature of the VE derivative: hydrophobic copolymers by using 
CEVE, amphiphilic copolymers by using TEGVE or via the grafting PEG750 chains onto a 
P(MDO-co-N3VE) copolymer, or hydrophilic copolymers by using PEG2000VE. The different 
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copolymers were then formulated into nanoparticles by the nanoprecipitation technique using 
either PEG-based surfactants for hydrophobic copolymers, without surfactant for amphiphilic 
ones and blended with PMDO for hydrophilic copolymers. These different formulation 
options conducted to P(MDO-co-VE) nanoparticles, most of them exhibiting average 
diameters in the good window for drug delivery purposes and satisfying colloidal stability 
assessed for at least 2 weeks and up to 6 months. Degradation of the different copolymers was 
demonstrated in both accelerated, physiological and enzymatic conditions in presence of 
lipases. Importantly, whereas hydrolytic degradation in PBS proceeded similarly to that of 
PCL, incubation with lipases led to fast and complete degradation (ca. –95% in Mn decrease), 
which, to the best of our knowledge, has never been reported in the literature for vinyl 
copolymers obtained by rROP between CKA and traditional vinyl monomers. Preliminary 
cytotoxicity assays were performed on two representative cell lines and led to high cell 
viabilities at concentrations higher than those reported for poly(alkyl cyanoacrylate) 
nanoparticles which represent so far the only example of vinyl polymer nanoparticles that 
reached advanced clinical trials against cancer.  
In conclusion, this new copolymerization system can give access to PCL-like materials 
that degrade like PCL, but with the advantage of being easily functionalized through a broad 
range of commercially available or accessible vinyl ether derivatives. This is of high 
importance for the design of degradable and functional nanoparticles for drug delivery 
applications. 
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The Supporting Information is available free of charge on the ACS Publications website at 
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SEC chromatograms of the (co)polymers. DLS data of the nanoparticles. SEC chromatograms 
and evolution of the Mn with time of the copolymers during degradation.  
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